Glenmark to launch Desonide topical ointment in US

Glenmark Pharmaceuticals Inc said it has got the go-ahead to launch the generic version of Perrigo’s anti-inflammation ointment Desonide Ointment in the US.

Desonide Ointment, 0.05% had annual sales of approximately $23.4 million for the 12 month period ending July 2017, according to IMS Health sales data.

Glenmark’s current portfolio consists of 124 products authorized for distribution in the U.S. marketplace and 62 ANDA’s (generic applications) pending approval with the U.S. FDA.

“In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio,” the company said.

The pharmaceutical company, headquartered in Mumbai, was founded in 1977 by Gracias Saldanha as a generic drug and active pharmaceutical ingredient manufacturer.

The company initially sold its products in India, Russia, and Africa, and went public in India in 1999.